Soybean- and Lupin-Derived Peptides Inhibit DPP-IV Activity on In Situ Human Intestinal Caco-2 Cells and Ex Vivo Human Serum

about

Bioactive Peptides from Germinated Soybean with Anti-Diabetic Potential by Inhibition of Dipeptidyl Peptidase-IV, α-Amylase, and α-Glucosidase Enzymes

P2860

Q59138330-F8ED604D-CA7B-4EB9-8DD6-9588AD78145E

P2860

Soybean- and Lupin-Derived Peptides Inhibit DPP-IV Activity on In Situ Human Intestinal Caco-2 Cells and Ex Vivo Human Serum

Item

http://www.wikidata.org/entity/Q58784788

description

im August 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published on 13 August 2018

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в серпні 2018

@uk

name

Soybean- and Lupin-Derived Pep ...... Cells and Ex Vivo Human Serum

@en

Soybean- and Lupin-Derived Pep ...... Cells and Ex Vivo Human Serum

@nl

type

Item

label

Soybean- and Lupin-Derived Pep ...... Cells and Ex Vivo Human Serum

@en

Soybean- and Lupin-Derived Pep ...... Cells and Ex Vivo Human Serum

@nl

prefLabel

Soybean- and Lupin-Derived Pep ...... Cells and Ex Vivo Human Serum

@en

Soybean- and Lupin-Derived Pep ...... Cells and Ex Vivo Human Serum

@nl

P1476

Soybean- and Lupin-Derived Pep ...... Cells and Ex Vivo Human Serum

@en

P2093

Carlotta Bollati

http://www.w3.org/2001/XMLSchema#string

Carmen Lammi

http://www.w3.org/2001/XMLSchema#string

Giulia Ranaldi

http://www.w3.org/2001/XMLSchema#string

Yula Sambuy

http://www.w3.org/2001/XMLSchema#string

P2860

DPP4 in Diabetes

Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses

The Caco-2 cell line as a model of the intestinal barrier: influence of cell and culture-related factors on Caco-2 cell functional characteristics.

Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV.

Improved glucose regulation in type 2 diabetic patients with DPP-4 inhibitors: focus on alpha and beta cell function and lipid metabolism.

The development of bioactive peptides from dietary proteins as a dipeptidyl peptidase IV inhibitor for the management of type 2 diabetes.

Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.

DPP4 inhibitors: a new approach in diabetes treatment.

DPP-4 inhibitors: impact on glycemic control and cardiovascular risk factors.

Overview of food products and dietary constituents with antidiabetic properties and their putative mechanisms of action: a natural approach to complement pharmacotherapy in the management of diabetes.

P304

1082

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3390/NU10081082

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Simonetta Ferruzza

Anna Arnoldi

P577

2018-08-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30104520

http://www.w3.org/2001/XMLSchema#string

P932

6115767

http://www.w3.org/2001/XMLSchema#string

Soybean- and Lupin-Derived Peptides Inhibit DPP-IV Activity on In Situ Human Intestinal Caco-2 Cells and Ex Vivo Human Serum

about

P2860

P2860

Soybean- and Lupin-Derived Peptides Inhibit DPP-IV Activity on In Situ Human Intestinal Caco-2 Cells and Ex Vivo Human Serum

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P932